One-shot gene therapy aims to help boys with duchenne walk and climb stairs

NCT ID NCT07160634

First seen Oct 31, 2025 · Last updated May 15, 2026 · Updated 32 times

Summary

This study tests a single intravenous dose of SGT-003, a gene therapy, in 80 boys with Duchenne muscular dystrophy who can still walk. The goal is to see if it improves their ability to stand up, walk, and climb stairs compared to a placebo. All participants will receive the therapy eventually, and they will be followed for at least 5 years.

Disclaimer Read more

This is a summary of the original study . Summaries may miss details or leave out important information. Before applying or accepting participation, make sure you have read and understood the full study. Curemydisease.com takes no responsibility whatsoever for anything missed, misunderstood, or acted upon as a result of our summary — we know it does not capture everything.

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for DUCHENNE MUSCULAR DYSTROPHY are added.

Our safety recommendation!

By submitting, you agree to our Terms of use

Contacts and locations

Study contacts

  • Contact

    Phone: •••-•••-•••• Email: •••••@•••••

Locations

  • BC Children's Hospital

    RECRUITING

    Vancouver, British Columbia, Canada

    Contact

    Contact Phone: •••-•••-•••• Email: •••••@•••••

  • The Children's Hospital of Westmead

    RECRUITING

    Sydney, New South Wales, Australia

    Contact Phone: •••-•••-•••• Email: •••••@•••••

    Contact

Conditions

Explore the condition pages connected to this study.